Inovio Pharmaceuticals Inc (NASDAQ:INO) announced the appointment of David B. Weiner, Ph.D. to its Board of Directors. Weiner is well-known for his knowledge and hands on experience in the DNA immunotherapy, and also called the “Father of DNA Vaccines And immunotherapies.”
Insights of Matter
Weiner and Inovio’s CEO, J. Joseph Kim, Ph.D., co-founded VGX Pharmaceuticals in the year 2000. A few years later, VGX became Inovio via a merger transaction. The day VGX was born, Weiner was appointed as the Chairman of its Scientific Advisory Board; he will continue to serve this position even after appointment to company’s Board of Directors.
Weiner has always tried to contribute to the industry in every possible way. Recently, he joined The Wistar Institute as its EVP and Director. After a successful tenure at the University of Pennsylvania and University’s Perelman School of Medicine, Weiner retired from his position on March 1, 2016. At University of Perelman School of Medicine, he chaired the Gene Therapy and Vaccine Program, and at the University of Pennsylvania, he was Emeritus Professor, Department of Laboratory Medicine & Pathology.
The senior management team of Inovio is delighted to have Weiner on company’s Board of Directors. According to Dr. J. Joseph Kim, CEO & President, Inovio, over the last many years, innovation has played a crucial role in company’s growth. Although product commercialization and business development are necessary to take a business to newer heights, it’s the innovation that helps any company achieve excellence. Weiner’s experience, knowledge and skill-set will prove to be very crucial for Inovio in the coming months.
Gene vaccines and immunology are likely to witness a boost in the demand; Weiner’s presence on company’s board will come handy at that time. Going forward, Inovio will take many more such steps to forge ahead and handle rising competition in the best possible manner.
